Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target?

Introduction

Critical illness is a life-threatening disease by definition. Patients treated for critical illness in the intensive care unit have underlying causes such as infection, trauma, major surgery, hemorrhagic shock, pancreatitis and other major insults. Despite maximal supportive care, severely ill patients treated in intensive care units are still likely to die, usually after an episode of increasing failure of multiple organs [ 1 ].

The mechanisms that underlie multiple organ dysfunction syndrome (MODS) are not known [ 2 ], although several have been proposed, including overwhelming infection or immune response, immune paralysis, occult oxygen debt and mitochondrial dysfunction [ 3 – 5 ]. Although these potential mechanisms have features in common, it is not clear whether MODS is a final common pathway or when it is engaged. The innate and adaptive immune systems, coagulation, and hormonal and neuronal signalling are undoubtedly involved and are all connected. For example, the hypoxic response is linked to innate immunity and inflammation by the transcription factor nuclear factor-κB (NF-κB) [ 6 ]. It is no coincidence that the few interventions that appear to be of benefit, although this is still under debate, have pleiotropic mechanisms of action [ 7 – 9 ]. Thus, it seems reasonable to study the intersections between and within cellular and molecular systems to elucidate the interactions and to develop therapeutic options.

One of the central cellular players in this system is the endothelial cell (EC). Once thought to serve as an inert vascular lining, ECs are highly heterogeneous and constitute an active disseminated organ throughout the circulatory system. ECs form the border between every organ and the bloodstream and thus with the rest of the body. The EC receives and gives signals, stores active substances of multiple systems, and regulates the passage of fluids, electrolytes, proteins and cells. The EC has a time and place dependent phenotype that is dynamically controlled, and its reactions to stimuli are specific to organ and vascular bed [ 10 – 13 ]. The EC merits robust investigation in critical illness, as in vascular medicine [ 14 ].

ECs fulfil three functions. First, they participate in the formation of new blood vessels. This is important in embryogenesis and organogenesis in normal physiology and in wound repair, but it is considered pathologic in tumour growth and diabetes [ 15 ]. Second, in the adult organism, ECs help to maintain homeostasis, including fluid, electrolyte and protein transport, and cell migration into and out of the vessel, and to regulate blood flow. Third, ECs react and respond to disturbances of homeostasis (for example, in inflammation, coagulation and hypoxia/reperfusion).

All three functions are involved in MODS, in which ECs are shed, blood flow regulation is hampered, vessels become leaky, cells migrate out of the vessel and into the surrounding tissue, and coagulation and inflammation pathways are activated [ 16 ]. The machinery involved – receptors, signalling pathways and effectors – is largely the same in each function, but the net effect is determined by the balance between the parts of the machinery and the context [ 15 ].

The angiopoietin/Tie2 signalling system (Ang/Tie system) appears to be crucial in all three functions [ 17 , 18 ]. The Ang/Tie system, which was discovered after vascular endothelial growth factor (VEGF) and its receptors, is mainly restricted to EC regulation and is the focus of this review. Accumulating evidence suggests that this system is non-redundant and is involved in multiple MODS-related pathways. All components of potential pathophysiological mechanisms in MODS should be viewed within their own context, because all systems are mutually dependent. Thus, examination of the Ang/Tie system might offer insight into the mechanisms underlying MODS and provide opportunities for therapeutic intervention.

Is the Ang/Tie system involved in critical illness?

The notion that the Ang/Tie system contributes to disease pathogenesis is supported by clinical studies and studies in animal models, and by the relation between symptoms of critical illness and disturbances in this system. In mice, Ang-2 over-expression in glomeruli causes proteinuria and apoptosis of glomerular ECs [ 19 ]. In a rat model of glomerulonephritis, Tie2 is over-expressed by ECs, and Ang-1 and Ang-2 are over-expressed by podocytes in a time-dependent manner during the repair phase [ 20 ]. Therefore, Ang/Tie might be involved in renal failure and repair.

Lung dysfunction is common in critical illness, and evidence of Ang/Tie involvement has been found in animal models. In a rat model of acute respiratory distress syndrome, Ang-1 reduces permeability and inflammation, whereas Tie2 deficiency increases damage [ 21 ]. In an experimental model of asthma, Ang-1 mRNA was decreased, and Ang-1 supplementation decreased alveolar leakage and NF-κB-dependent inflammation [ 22 ]. In hypoxia-induced pulmonary hypertension in rats, decreased activity of the Tie2 pathway contributed to right ventricular load, and this effect was antagonized by Ang-1 [ 23 ]. On the other hand, a causative role for Ang-1 in pulmonary hypertension has also been suggested [ 24 ]. In hyperoxic lung injury, Ang-2 is involved in lung permeability and inflammation [ 25 ].

Ang/Tie also may contribute to critical illness in patients with pulmonary conditions. Ang-1 and Ang-2 concentrations in sputum from asthma patients correlated with airway microvascular permeability [ 26 ]. In patients with exudative pleural effusion, the Ang-2 level was increased whereas Ang-1 was unchanged [ 27 ]. Ang-2 levels are associated with pulmonary vascular leakage and the severity of acute lung injury. Plasma from patients with acute lung injury and high Ang-2 concentrations disrupts junctional architecture in vitro in human microvascular ECs [ 28 , 29 ].

Patients with cardiovascular disorders also exhibit changes in the Ang/Tie system. Circulating Ang-1 concentrations are stable in patients with atrial fibrillation, but Ang-2 concentrations are increased, along with markers of platelet activation, angiogenesis and inflammation [ 30 ]. Patients with hypertension resulting in endorgan damage have increased levels of circulating Ang-1, Ang-2, Tie2 and VEGF [ 31 ]. Congestive heart failure is associated with elevated plasma levels of Ang-2, Tie2 and VEGF, but normal levels of Ang-1 [ 32 ]. A similar pattern is seen in acute coronary syndrome [ 33 ].

Circulating levels of components of the Ang/Tie system have been measured in patients admitted to the critical care unit. In trauma patients plasma Ang-2, but not plasma Ang-1 or VEGF, was increased early after trauma, and the level correlated with disease severity and outcome [ 34 ]. In children with sepsis and septic shock, Ang-2 levels in plasma were increased and once again correlated with disease severity, whereas Ang-1 levels were decreased [ 35 ]. The same Ang-1/Ang-2 pattern is seen in adults with sepsis [ 28 , 29 , 36 – 39 ]. The results of studies of the Ang/Tie system in humans are summarized in Table 1 . In sepsis, VEGF and its soluble receptor sFLT-1 (soluble VEGFR-1) are also increased in a disease severity-dependent manner [ 40 – 42 ]. The picture that emerges from these studies is that the Ang/Tie signalling system appears to play a crucial role in the symptoms of MODS. Findings in animal models and in patients suggest that Ang-1 stabilizes ECs and Ang-2 prepares them for action. The close relation with VEGF is also apparent. Table 1 Clinical studies of Ang-1, Ang-2 and soluble Tie2 in critically ill patients Study Patients Ang-1 Ang-2 Soluble Tie2 Clinical effects Lee et al . [ 33 ] ACS: 82 AMI, 44 unstable angina, 40 stable CAD 40 HCs NS Higher in AMI versus HCs, SA, unstable angina Higher in AMI versus HCs, SA, unstable angina ND Kugathasan et al . [ 23 ] PAH: 6 idiopathic, 7 with other disease 8 HCs NS NS Tie2 mRNA higher in lung of PAH patients versus HCs ND Parikh et al . [ 28 ] ICU patients: 17 severe sepsis, 5 mild sepsis 29 HCs NS Higher in severe sepsis versus HCs ND Ang-2 levels correlate with low PaO 2 /FiO 2 Gallagher et al . [ 180 ] Vascular leakage: 14 IL-2, 14 IL-2+bevacizumab ND Higher during therapy ND Ang-2 levels rise on days of IL-2 therapy; high levels on day 3 predict vascular leakage (stop therapy) Gallagher et al . [ 29 ] ARDS: 45 ICU, 18 ARDS ND Higher in ARDS versus ICU patients; in ARDS, higher in nonsurvivors ND High levels of Ang-2 on day patient meets ARDS criteria. Ang-2 levels in ARDS patients correlate with mortality Giuliano et al . [ 35 ] Septic shock children: 20 SIRS 20 sepsis, 61 septic shock 15 HCs Ang-1 lower in septic shock versus sepsis and SIRS Higher in septic shock versus HCs, SIRS and sepsis ND ND Orfanos et al . [ 37 ] ICU patients: 6 no SIRS, 8 SIRS, 16 sepsis, 18 severe sepsis, 13 septic shock ND Higher in severe sepsis versus no SIRS and sepsis ND Ang-2 levels related to severe sepsis and TNF-α levels Scholz et al . [ 181 ] 180 liver cirrhosis patients 40 HCs ND Higher in cirrhosis versus HCs ND ND Ganter et al . [ 34 ] 208 trauma patients in ER Unchanged Higher within 30 minutes after ER admission ND Ang-2 levels correlate with met ISS and mortality. Ang-2 higher in nonsurvivors van der Heijden et al . [ 39 ] 24 sepsis, 88 nonseptic critically ill 15 HCs Ang-1 lower in sepsis and critical illness versus HCs Higher in critically ill patients; higher in septic than nonseptic patients ND Ang-2 levels associated with pulmonary permeability oedema and severity of ALI in septic and nonseptic critically ill patients Lukasz et al . [ 36 ] 94 critically ill medical ICU patients 30 HCs Ang-1 correlated negatively with SOFA Score Ang-2 correlates positively with SOFA Score ND Ang-1 correlates negatively and Ang-2 positively with SOFA score Siner et al . [ 38 ] Critically ill patients: 20 nonseptic (ICU), 10 sepsis, 12 severe sepsis, 24 septic shock ND Ang-2 increases with severity of sepsis ND Increase in Ang-2 associated with severity of illness and hospital mortality ACS, acute coronary syndrome; AMI, acute myocardial infarction; ARDS, acute respiratory distress syndrome; CAD, coronary artery disease; ER, emergency room; Fi oxygen; HC, healthy control; ICU, intensive care unit; IL, interleukin; ISS, International Severity Score; ND, not determined; NS, not significant; PAH, pulmonary arterial hypertension; Pa pulmonary artery oxygen tension; SA, stable angina; SOFA, Sequential Organ Failure Assessment score; TNF, tumour necrosis factor.

The angiopoietin signalling system

Ligands and receptors

The angiopoietin signalling system consists of four ligands and two receptors (Figure 1 ). The ligands are Ang-1 to Ang-4, the best studied being Ang-1 and Ang-2 [ 17 , 43 – 45 ]. The roles of Ang-3 (the murine orthologue of Ang-4) and Ang-4 are much less clear [ 18 ]. Angiopoietins are 70-kDa glycoproteins that contain an amino-terminal angiopoietin-specific domain, a coiled-coil domain, a linker peptide and a carboxyl-terminal fibrinogen homology domain [ 17 , 44 , 46 , 47 ]. Ang-1 and Ang-2 bind to Tie2 after polymerization of at least four (Ang-1) and two (Ang-2) subunits [ 48 , 49 ]. The dissimilarity between Ang-1 and Ang-2 signalling lies in subtle differences in the receptor binding domain that lead to distinct intracellular actions of the receptor; differential cellular handling of both receptor and ligands after binding and signalling initiation may also play a role [ 49 , 50 ]. Figure 1 A schematic model of the angiopoietin-Tie2 ligand-receptor system . Quiescent endothelial cells are attached to pericytes that constitutively produce Ang-1. As a vascular maintenance factor, Ang-1 reacts with the endothelial tyrosine kinase receptor Tie2. Ligand binding to the extracellular domain of Tie2 results in receptor dimerization, autophosphorylation, docking of adaptors and coupling to intracellular signalling pathways. Signal transduction by Tie2 activates the PI3K/Akt cell survival signalling pathway, thereby leading to vascular stabilization. Tie2 activation also inhibits the NF-κB-dependent expression of inflammatory genes, such as those encoding luminal adhesion molecules (for example, intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin). Ang-2 is stored and rapidly released from WPBs in an autocrine and paracrine fashion upon stimulation by various inflammatory agents. Ang-2 acts as an antagonist of Ang-1, stops Tie2 signalling, and sensitizes endothelium to inflammatory mediators (for example, tumour necrosis factor-α) or facilitates vascular endothelial growth factor-induced angiogenesis. Ang-2-mediated disruption of protective Ang-1/Tie2 signalling causes disassembly of cell-cell junctions via the Rho kinase pathway. In inflammation, this process causes capillary leakage and facilitates transmigration of leucocytes. In angiogenesis, loss of cell-cell contacts is a prerequisite for endothelial cell migration and new vessel formation. Ang, angiopoietin; NF-κB, nuclear factor-κB; PI3K, phosphoinositide-3 kinase; WPB, Weibel-Palade body.

The receptors are Tie1 and Tie2 [ 51 ]. Tie2 is a 140-kDa tyrosine kinase receptor with homology to immunoglobulin and epidermal growth factor [ 47 , 52 ]. Tie receptors have an amino-terminal ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain [ 51 ]. Ligand binding to the extracellular domain of Tie2 results in receptor dimerization, autophosphorylation and docking of adaptors, and coupling to intracellular signalling pathways [ 47 , 53 – 55 ]. Tie2 is shed from the EC and can be detected in soluble form in normal human serum and plasma; soluble Tie2 may be involved in ligand scavenging without signalling [ 56 ]. Tie2 shedding is both constitutive and induced; the latter can be controlled by VEGF via a pathway that is dependent on phosphoinositide-3 kinase (PI3K) and Akt [ 57 ]. Shed soluble Tie2 can scavenge Ang-1 and Ang-2 [ 56 ]. Tie1 does not act as a transmembrane kinase; rather, it regulates the binding of ligands to Tie2 and modulates its signalling [ 58 – 60 ].

Origin of ligands and distribution of receptors

Ang-1 is produced by pericytes and smooth muscle cells (Figure 1 ). In the glomerulus, which lacks pericytes, Ang-1 is produced by podocytes [ 61 ]. Ang-1 has a high affinity for the extracellular matrix, and so circulating levels do not reflect tissue levels, which in part is probably responsible for the constitutive phosphorylation of Tie2 in quiescent endothelium [ 62 – 65 ]. Ang-2 is produced in ECs and stored in Weibel-Palade bodies (WPBs) [ 66 , 67 ]. The release of Ang-2 from WPBs by exocytosis can be regulated independently of the release of other stored proteins [ 68 ]. Tie2 is expressed predominantly by ECs, although some subsets of macrophages and multiple other cell types express Tie2 at low levels [ 69 , 70 ]. In ECs, Tie2 is most abundant in the endothelial caveolae [ 71 ].

Genetics and transcriptional regulation of components of the Ang/Tie system

The Ang-1 and Ang-2 genes are located on chromosome 8. Functional polymorphisms have not been identified in the Ang-1 gene, but three have been identified in the coding region of Ang-2 [ 72 ]. In ECs under stress, Ang-2 mRNA expression is induced by VEGF, fibroblast growth factor 2 and hypoxia [ 44 , 73 ]. Upregulation of Ang-2 induced by VEGF and hypoxia can be abolished by inhibiting tyrosine kinase or mitogen-activated protein kinase [ 73 ]. Ang-2 mRNA expression can be downregulated by Ang-1, Ang-2, or transforming growth factor [ 74 ]. After inhibition of PI3K by wortmannin, Ang-2 mRNA production is induced by the transcription factor FOXO1 (forkhead box O1) [ 75 ]. EC-specific Ang-2 promoter activity is regulated by Ets-1 and the Ets family member Elf-1 [ 76 , 77 ]. Because Tie2 signalling is required under circumstances that usually hamper cell metabolism, its promoter contains repeats that ensure transcription under difficult circumstances, including hypoxia [ 78 ].

The Tie2 downstream signalling pathway

Tie2 is present in phosphorylated form in quiescent and activated ECs throughout the body [ 62 ]. Signalling is initiated by autophosphorylation of Tie2 after Ang-1 binding and is conducted by several distinct pathways [ 54 , 71 , 79 , 80 ]. Tie2 can also be activated at cell-cell contacts when Ang-1 induces Tie2/Tie2 homotypic intercellular bridges [ 65 ]. In human umbilical vein endothelial cells (HUVECs), Ang/Tie signalling resulted in 86 upregulated genes and 49 down-regulated genes [ 81 , 82 ]. Akt phosphorylation by PI3K with interaction of nitric oxide is the most important intracellular pathway [ 51 , 83 – 86 ]; however, ERK1/2, p38MAPK, and SAPK/JNK can also participate in Ang/Tie downstream signalling [ 71 , 81 , 84 , 87 – 90 ]. Endothelial barrier control by Ang-1 requires p190RhoGAP, a GTPase regulator that can modify the cytoskeleton [ 80 ]. The transcription factors FOXO1, activator protein-1, and NF-κB are involved in Ang/Tie-regulated gene transcription [ 75 , 91 – 93 ]. Ang-1-induced signalling is has also been implicated in cell migration induced by reactive oxygen species [ 94 ]. ABIN-2 (A20-binding inhibitor of NF-κB 2), an inhibitor of NF-κB, is involved in Ang-1-regulated inhibition of endothelial apoptosis and inflammation in HUVECs [ 93 ]. However, the downstream signalling of Tie2 varies depending on cell type and localization and whether a cell-cell or cell-matrix interaction in involved, which results in spatiotemporally different patterns of gene expression. For example, Ang-1/Tie2 signalling leads to Akt activation within the context of cell-cell interaction, but it leads to ERK activation in the context of cell-matrix interaction. The microenvironment of the receptor in the cell membrane plays a central role in this signal differentiation. Adaptor molecules such as DOK and SHP2 and the availability of substrate determine which protein is phosphorylated [ 95 ].

Signal regulation

After binding of Ang-1, and to a lesser extent Ang-2, Tie2 is internalized and degraded, and Ang-1 is shed in a reusable form [ 50 ]. VEGF is an important co-factor that can exert different effects on Ang-1 and Ang-2 signalling [ 88 ]. Ang-2 is anti-apoptotic in the presence of VEGF but induces EC apoptosis in its absence [ 96 ]. Autophosphorylation and subsequent signalling are inhibited by heteropolymerization of Tie1 and Tie2 [ 59 ]. Although the Ang/Tie system appears to play its role mainly in paracrine and autocrine processes, its circulating components have been found in plasma. The significance of this finding in health and disease has yet to be determined.

Summary

The Ang/Tie system is an integrated, highly complex system of checks and balances (Figure 1 ) [ 45 , 54 ]. The response of ECs to Ang-1 and Ang-2 depends on the location of the cells and the biological and biomechanical context [ 97 , 98 ]. It is believed that PI3K/Akt is among the most important downstream signalling pathways and that VEGF is one of the most important modulators of effects. Below we describe in more detail how this system responds to changes in homeostatic balances under various conditions of damage and repair.

Ang/Tie signalling system in health and disease

Angiogenesis, inflammation and homeostasis are highly related, and the Ang/Tie system lies at the intersection of all three processes [ 99 , 100 ]. The Ang/Tie system is critically important for angiogenesis during embryogenesis, but in healthy adults its function shifts toward maintenance of homeostasis and reaction to insults. Except for follicle formation, menstruation and pregnancy, angiogenesis in adults is disease related. Neoplasia-associated neoangio-genesis and neovascularization in diabetes and rheumatoid arthritis are unfavourable events, and improper angiogenesis is the subject of research in ischaemic disorders and atherosclerosis. Finally, failure to maintain homeostasis and an inappropriate reaction to injury are detrimental features in critical illness.

Angiogenesis

Angiogenesis is dependent on multiple growth factors and receptors and their signalling systems and transcriptional regulators [ 101 ]. The process is complex and encompasses the recruitment of mobile ECs and endothelial progenitor cells, the proliferation and apoptosis of these cells, and reorganization of the surroundings [ 102 ]. To form stable new blood vessels, the response must be coordinated in time and space, and the Ang/Tie system is involved from beginning to end. To prepare for angiogenesis, Ang-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism [ 44 , 103 ]. Before vascular sprouting starts, focal adhesion kinase and proteinases such as plasmin and metallo-proteinases are excreted [ 85 ]. Often, this stage is preceded by activation of innate immunity and inflammation [ 104 ]. Apparently, the machinery to clean up after the work has been finished is installed before the work is commenced, again illustrating the close relations among the different processes [ 104 ].

Ang-1 maintains and, when required, restores the higher order architecture of growing blood vessels [ 43 , 44 , 105 , 106 ]. This is achieved by inhibiting apoptosis of ECs by Tie2-mediated activation of PI3K/Akt signalling [ 107 – 109 ]. Ang-1/Tie2 signalling is involved in angiogenesis induced by cyclic strain and hypoxia [ 110 , 111 ]. Although its role is less clear, Tie1 might be involved in EC reactions to shear stress [ 112 ]. Ang-1 is a chemoattractant for ECs [ 83 – 85 ], and both Ang-1 and Ang-2 have proliferative effects on those cells [ 98 , 113 ]. At the end of a vascular remodelling phase, Ang-2 induces apoptosis of ECs for vessel regression in competition with the survival signal of Ang-1 [ 106 ]. This apoptotic process requires macrophages, which are recruited by Ang-2 [ 70 , 114 ].

ECs require support from surrounding cells such as pericytes, podocytes, and smooth muscle cells [ 63 ]. These cells actively control vascular behaviour by producing signalling compounds (for instance, Ang-1 and VEGF) that govern the activity and response of ECs [ 61 ]. To attract ECs, Ang-1 secreted by support cells binds to the extracellular matrix. In quiescent ECs, this binding results in Tie2 movement to the site of cell-cell interaction. In mobile ECs, Ang-1 polarizes the cell with Tie2 movement abluminal site [ 65 ]. In tumour angiogenesis and in inflammation, Ang-2 recruits Tie2-positive monocytes and causes them to release cytokines and adopt a pro-angiogenic phenotype [ 111 ].

Homeostasis

The Ang/Tie system provides vascular wall stability by inducing EC survival and vascular integrity. However, this stability can be disrupted by Ang-2 injection, which in healthy mice causes oedema [ 28 , 79 , 115 , 116 ] that can be blocked by systemic administration of soluble Tie2 [ 115 ]. Ang-2 can impair homeostatic capacity by disrupting cell-cell adhesion through E-cadherin discharge and EC contraction [ 28 , 117 ]. In contrast, through effects on intracellular signalling, the cytoskeleton and junction-related molecules, Ang-1 reduces leakage from inflamed venules by restricting the number and size of gaps that form at endothelial cell junctions [ 80 , 118 , 119 ]. Ang-1 also suppresses expression of tissue factor induced by VEGF and tumour necrosis factor (TNF)-α, as well as expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and E-selectin. As a result, endothelial inflammation is suppressed [ 120 – 123 ].

In primary human glomerular ECs in vitro , Ang-1 stabilizes the endothelium by inhibiting angiogenesis, and VEGF increases water permeability [ 124 ]. Similar observations were made in bovine lung ECs and immortalized HUVECs, in which Ang-1 decreased permeability, adherence of polymorphonuclear leucocytes and interleukin-8 production [ 123 ].

Injury

Reaction to injury can be seen as an attempt to maintain homeostasis under exceptional conditions. ECs can be affected by several noxious mechanisms. The Ang/Tie system is considered crucial in fine-tuning their reaction to injury and in containing that reaction. Ang-2-deficient mice cannot mount an inflammatory response to peritonitis induced chemically or with Staphylococcus aureus [ 125 ], but they can mount a response to pneumonia, suggesting the existence of inflammatory reactions for which Ang-2 is not mandatory. Ang-2 sensitizes ECs to activation by inflammatory cytokines. In Ang-2-deficient mice, leucocytes do roll on activated endothelium but they are not firmly attached, owing to the lack of Ang-2-dependent upregulation of adhesion molecules and the dominance of Ang-1-regulated suppression of adhesion molecules [ 120 – 123 , 125 ].

In bovine retinal pericytes, hypoxia and VEGF induce Ang-1 and Tie2 gene expression acutely without altering Ang-2 mRNA levels. The opposite occurs in bovine aortic ECs and microvascular ECs, underscoring the heterogeneity of ECs from different microvascular beds [ 73 , 126 , 127 ].

Lipopolysaccharide (LPS) and pro-inflammatory cytokines can shift the Ang/Tie balance, rouse ECs from quiescence and provoke an inflammatory response. In rodents LPS injection induces expression of Ang-2 mRNA and protein and reduces the levels of Ang-1, Tie2 and Tie2 phosphorylation in lung, liver and diaphragm within 24 hours, which may promote or maintain vascular leakage. The initial increase in permeability is probably due to release of Ang-2 stored in WPBs [ 39 , 128 ]. In a mouse model of LPS-induced lung injury, pulmonary oedema was found to be related to the balance between VEGF, Ang-1 and Ang-4 [ 129 ]. In a comparable model, Ang-1-producing transfected cells reduced alveolar inflammation and leakage [ 130 ].

In choroidal ECs, TNF induces Ang-2 mRNA and protein before affecting Ang-1 and VEGF levels [ 131 ]. In HUVECs, TNF-induced upregulation of Ang-2 is mediated by the NF-κB pathway [ 132 ], and TNF-induced Tie2 expression can be attenuated by both Ang-1 and Ang-2. Without TNF stimulation, only Ang-1 can reduce Tie2 expression [ 133 ]. Ang-2 sensitizes ECs to TNF, resulting in enhanced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin [ 74 , 125 , 134 ]. By inhibiting those endothelial adhesion molecules, Ang-1 decreases leucocyte adhesion [ 122 ].

Angiopoietins can mediate the synthesis of platelet-activating factor by ECs to stimulate inflammation [ 90 ]. Moreover, both Ang-1 and Ang-2 can translocate P-selectin from WPBs to the surface of the EC [ 135 ], and both can also increase neutrophil adhesion and chemotaxis and enhance those processes when they are induced by interleukin-8 [ 86 , 136 , 137 ].

In a rat model of haemorrhagic shock, Ang-1 reduced vascular leakage, and it inhibited microvascular endothelial cell apoptosis in vitro and in vivo [ 107 , 138 ]. In this model, Ang-1-promoted cell survival was partly controlled through integrin adhesion [ 139 ]. It has been suggested that EC apoptosis in haemorrhagic shock contributes to endothelial hyperpermeability [ 140 – 142 ]. Apoptosis is one of the reactions to MODS-related injury as demonstrated in hypoxia/reperfusion [ 143 ].

Cell adhesion

Ang-1 and Ang-2 are involved in cell-cell and cell-matrix binding [ 139 , 144 – 146 ]. Endothelial permeability is greatly dependent on cell-cell adhesion. The major adherens junction is largely composed of vascular-endothelial cadherin. This complex can be disrupted by VEGF, leading to increased vascular permeability [ 147 , 148 ], which can be antagonized by Ang-1 [ 149 , 150 ]. ECs can also bind to the matrix through the binding of Ang-1 to integrins, which can mediate some of the effects of Ang-1 without Tie2 phosphorylation [ 146 , 151 ]. At low Ang-1 concentrations, integrin and Tie2 can cooperate to stabilize ECs [ 151 ]. Ang-2 might play a role in inflammatory diseases such as vasculitis by disrupting the cell-cell junction and inducing denudation of the basal membrane [ 152 ]. Ang-1 can mediate the translocation of Tie2 to endothelial cell-cell contacts and induce Tie2-Tie2 bridges with signal pathway activation, leading to diminished paracellular permeability [ 65 ].

Summary

In the mature vessel, Ang-1 acts as a paracrine signal to maintain a quiescent status quo , whereas Ang-2 induces or facilitates an autocrine EC response [ 74 , 153 ]. In general, Ang-1 can be viewed as a stabilizing messenger, causing continuous Tie2 phosphorylation, and Ang-2 as a destabilizing messenger preparing for action [ 17 ]. Attempts to unravel the exact molecular mechanisms that control the system are complicated by microenvironment-dependent endothelial phenotypes and reactivity and by flow type-dependent reactions to dynamic changes [ 13 , 154 , 155 ]. Hence, the EC must be viewed in the context of its surroundings – the pericyte at the abluminal site, and the blood and its constituents on the luminal site [ 64 ]. The Ang/Tie system certainly functions as one of the junctions in signal transduction and plays a key role in multiple cellular processes, many of which have been linked to MODS.

Targeting the Ang/Tie system in critical illness

A therapy should intervene in the right place and at the right time, with the proper duration of action and without collateral damage [ 156 , 157 ]. The Ang/Tie system is involved in many processes and lies at the intersection of molecular mechanisms of disease. Thus, interventions targeting this system might have benefits. As in other pleiotropic systems, however, unexpected and unwanted side effects are a serious risk. The absence of redundant systems to take over the function of Ang/Tie2 has the advantage that the effect of therapeutic intervention cannot easily be bypassed by the cell. On the other hand, because the cell has no escape, the effect may become uncontrolled and irreversible. Moreover, the exact function of the Ang/Tie system in the pathological cascade is not fully established. What we see in animal models and in patients is most probably the systemic reflection of a local process. We do not know whether this systemic reflection is just a marker of organ injury or even a mediator of distant organ involvement.

Of the three main functions of the Ang/Tie system, it is mainly angiogenesis that has been evaluated as a therapeutic target. So far, the focus of Ang/Tie modulation has been on inhibiting angiogenesis related to malignant and ophthalmological diseases and to complications of diabetes [ 158 , 159 ]. In peripheral arterial occlusive disease, stimulation of angiogenesis seems a logical strategy to attenuate the consequences of ongoing tissue ischaemia. In a rat model of hind limb ischaemia, combined delivery of Ang-1 and VEGF genes stimulated collateral vessel development to the greatest extent [ 160 , 161 ]. Thus far, therapy directed at VEGF has reached the clinic, but not therapy directed at Ang/Tie [ 162 ].

Targeting homeostasis and repair/inflammation in critically ill patients is an attractive option and has already led to the development of new drugs [ 45 , 158 , 163 ]. From current knowledge, one can speculate about the best options for therapy aimed at the Ang/Tie system. In critical illness, Ang-1 is considered to be the 'good guy' because it can create vascular stability and thus its activity should be supported. In contrast, Ang-2 appears to be a 'bad guy' that induces vascular leakage, so its activity should be inhibited [ 164 ].

Production of recombinant Ang-1 is technically challenging as Ang-1 is 'sticky' because of its high affinity for the extracellular matrix [ 165 ]. However, stable Ang-1 variants with improved receptor affinity have been engineered. A stable soluble Ang-1 variant has anti-permeability activity [ 165 ]. When injected intraperitoneally in mice, human recombinant Ang-1 can prevent LPS-induced lung hyperpermeability [ 80 ]. In diabetic mice, a stable Ang-1 derivative attenuated proteinuria and delayed renal failure [ 166 ], and manipulating the Ang-1/Ang-2 ratio changed infarct size [ 167 ]. A more profound Ang-1 effect can be achieved by locally stimulating Ang-1 production. In experimental acute respiratory distress syndrome, transfected cells expressing Ang-1 reduced alveolar inflammation and leakage [ 130 ]. An adenovirus construct encoding Ang-1 protected mice from death in an LPS model, and Ang-1 gene therapy reduced acute lung injury in a rat model [ 21 , 168 , 169 ]. In hypertensive rats, a plasmid expressing a stable Ang-1 protein reduced blood pressure and end-organ damage [ 170 ]. If used in a disease with a limited duration, as critical illness should be, virus/plasmid-driven production of Ang-1 could easily be shut down when it is no longer needed.

Manipulating Ang-2 activity is also difficult. Ang-2 stored in WPBs is rapidly released and must be captured immediately to prevent autocrine/paracrine disruption of protective Ang-1/Tie signalling. Soluble Tie2 or Ang-2 inhibitors should be effective [ 26 , 171 ]. Neutralizing antibodies against Ang-2 might also be an option. Replenishment of Ang-2 stores could be abolished by small interfering RNA techniques or spiegelmer/aptamer approaches [ 25 , 172 , 173 ].

However, no bad guy is all bad, and no good guy is all good. For example, Ang-1 has been linked to the development of pulmonary hypertension [ 174 ]. Also, under certain circumstances Ang-2 can act as a Tie2 agonist and exert effects similar to those of Ang-1 – an unexplained finding that illustrates our limited understanding of the Ang/Tie system [ 75 ]. Complete blockade of Ang-2 might also hamper innate immunity and revascularization.

Finding the right balance and timing will be the major challenge when developing therapies to target the Ang/Tie system. In the meantime, we might have already used Ang/Tie-directed therapy with the most pleiotropic of all drugs – corticosteroids. In the airways, steroids suppressed Ang-2 and increased Ang-1 expression [ 26 , 171 , 175 ]. Interventions further downstream targeting specific adaptor molecules, signalling pathways, or transcription factors have yet to be explored.

Diagnostic and prognostic opportunities

In patients with malignant disease, the Ang/Tie system might serve as a tumour or response marker. In patients with multiple myeloma, normalization of the Ang-1/Ang-2 ratio reflects a response to treatment with anti-angiogenesis medication [ 176 ]. In patients with non-small-cell lung cancer, Ang-2 is increased in serum and indicates tumour progression [ 177 ]. After allogeneic stem cell transplantation in patients with high-risk myeloid malignancies, the serum Ang-2 concentration predicts disease-free survival [ 178 ], possibly reflecting a relation between cancer-driven angiogenesis and Ang-2 serum level.

In nonmalignant disease, the levels of Ang/Tie system components correlate with disease severity [ 28 , 29 , 34 – 37 , 39 ]. However, current data are insufficient to justify the use of serum soluble Tie2/Ang levels for diagnostic and prognostic purposes. In critical illness, assessment of the Ang/Tie system in patients with different severities of disease and with involvement of different organ systems might help to define our patient population and allow us to rethink our concepts of MODS. In this way, such work may lead to enhanced diagnosis and prognostication in the future [ 2 ].

Conclusion

Accumulating evidence from animal and human studies points to the involvement of the Ang/Tie system in vascular barrier dysfunction during critical illness. Many processes in injury and in repair act through this nonredundant system. Thus far, only preliminary studies in critically ill patients have been reported. Methods to manipulate this system are available but have not been tested in such patients. The response to treatment is difficult to predict because of the pleiotropic functions of the Ang/Tie system, because the balance among its components appears to be more important than the absolute levels, and because the sensitivity of the endothelium to disease-related stimuli varies, depending on the environment and the organ involved. To avoid disappointment, further experimental and translational research must be carried out, and Ang/Tie modulation must not be introduced into the clinic prematurely. Implementing the results of this research in critical care represents an opportunity to show what we have learned [ 2 ]. Ang/Tie signalling is a very promising target and must not be allowed to become lost in translation [ 179 ].

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images. Authors’ original file for figure 1

Abbreviations

angiopoietin

angiopoietin/Tie2 signalling system

endothelial cell

human umbilical vein endothelial cell

lipopolysaccharide

multiple organ dysfunction syndrome

nuclear factor-κB

phosphoinositide-3 kinase

tumour necrosis factor

vascular endothelial growth factor

Weibel-Palade body.

Competing interests

The authors declare that they have no competing interests.

References

1. Wenzel RP Treating sepsis N Engl J Med 2002 347 966 967 12324551 10.1056/NEJMp020096

2. Marshall JC Sepsis: rethinking the approach to clinical research J Leukoc Biol 2008 83 471 482 18171697 10.1189/jlb.0607380

3. Singer M De Santis V Vitale D Jeffcoate W Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation Lancet 2004 364 545 548 15302200 10.1016/S0140-6736(04)16815-3

4. Bone RC Sir Isaac Newton, sepsis, SIRS, and CARS Crit Care Med 1996 24 1125 1128 8674323 10.1097/00003246-199607000-00010

5. Hotchkiss RS Swanson PE Freeman BD Tinsley KW Cobb JP Matuschak GM Buchman TG Karl IE Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction Crit Care Med 1999 27 1230 1251 10446814 10.1097/00003246-199907000-00002

6. Rius J Guma M Schachtrup C Akassoglou K Zinkernagel AS Nizet V Johnson RS Haddad GG Karin M NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha Nature 2008 453 807 811 18432192 10.1038/nature06905 PMC2669289

7. Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Fisher CJ Jr Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001 344 699 709 11236773 10.1056/NEJM200103083441001

8. Annane D Sebille V Charpentier C Bollaert PE Francois B Korach JM Capellier G Cohen Y Azoulay E Troche G Chaumet-Riffaut P Bellissant E Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock JAMA 2002 288 862 871 12186604 10.1001/jama.288.7.862

9. Berghe G Van den Wouters P Weekers F Verwaest C Bruyninckx F Schetz M Vlasselaers D Ferdinande P Lauwers P Bouillon R Intensive insulin therapy in the critically ill patients N Engl J Med 2001 345 1359 1367 11794168 10.1056/NEJMoa011300

10. Aird WC Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms Circ Res 2007 100 158 173 17272818 10.1161/01.RES.0000255691.76142.4a

11. Aird WC Phenotypic heterogeneity of the endothelium: II. Representative vascular beds Circ Res 2007 100 174 190 17272819 10.1161/01.RES.0000255690.03436.ae

12. van Meurs M Wulfert FM Knol AJ de Haes A Houwertjes M Aarts LP Molema G Early organ-specific endothelial activation during hemorrhagic shock and resuscitation Shock 2008 29 291 299 17704730 10.1097/SHK.0b013e318145a7c1

13. Langenkamp E Molema G Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer Cell Tissue Res 2009 335 205 222 18677515 10.1007/s00441-008-0642-4

14. Aird WC The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome Blood 2003 101 3765 3777 12543869 10.1182/blood-2002-06-1887

15. Bouis D Kusumanto Y Meijer C Mulder NH Hospers GA A review on pro- and anti-angiogenic factors as targets of clinical intervention Pharmacol Res 2006 53 89 103 16321545 10.1016/j.phrs.2005.10.006

16. Rafat N Hanusch C Brinkkoetter PT Schulte J Brade J Zijlstra JG Woude FJ van der van AK Yard BA Beck GC Increased circulating endothelial progenitor cells in septic patients: correlation with survival Crit Care Med 2007 35 1677 1684 17522579 10.1097/01.CCM.0000269034.86817.59

17. Brindle NP Saharinen P Alitalo K Signaling and functions of angiopoietin-1 in vascular protection Circ Res 2006 98 1014 1023 16645151 10.1161/01.RES.0000218275.54089.12 PMC2270395

18. Jones PF Not just angiogenesis: wider roles for the angiopoietins J Pathol 2003 201 515 527 14648654 10.1002/path.1452

19. Davis B Dei CA Long DA White KE Hayward A Ku CH Woolf AS Bilous R Viberti G Gnudi L Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia J Am Soc Nephrol 2007 18 2320 2329 17625119 10.1681/ASN.2006101093

20. Campean V Karpe B Haas C Atalla A Peters H Rupprecht H Liebner S Acker T Plate K Amann K Angiopoietin 1 and 2 gene and protein expression is differentially regulated in acute anti-Thy1.1 glomerulonephritis Am J Physiol Renal Physiol 2008 294 F1174 F1184 18272601 10.1152/ajprenal.00320.2007

21. McCarter SD Mei SH Lai PF Zhang QW Parker CH Suen RS Hood RD Zhao YD Deng Y Han RN Dumont DJ Stewart DJ Cell-based angiopoietin-1 gene therapy for acute lung injury Am J Respir Crit Care Med 2007 175 1014 1026 17322110 10.1164/rccm.200609-1370OC

22. Simoes DC Vassilakopoulos T Toumpanakis D Petrochilou K Roussos C Papapetropoulos A Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma Am J Respir Crit Care Med 2008 177 1314 1321 18356565 10.1164/rccm.200708-1141OC

23. Kugathasan L Dutly AE Zhao YD Deng Y Robb MJ Keshavjee S Stewart DJ Role of angiopoietin-1 in experimental and human pulmonary arterial hypertension Chest 2005 128 6 suppl 633S 642S 16373885 10.1378/chest.128.6_suppl.633S

24. Rudge JS Thurston G Yancopoulos GD Angiopoietin-1 and pulmonary hypertension: cause or cure? Circ Res 2003 92 947 949 12750304 10.1161/01.RES.0000074031.94558.99

25. Bhandari V Choo-Wing R Lee CG Zhu Z Nedrelow JH Chupp GL Zhang X Matthay MA Ware LB Homer RJ Lee PJ Geick A de Fougerolles AR Elias JA Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death Nat Med 2006 12 1286 1293 17086189 10.1038/nm1494 PMC2768268

26. Kanazawa H Nomura S Asai K Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients Chest 2007 131 1035 1041 17426207 10.1378/chest.06-2758

27. Kalomenidis I Kollintza A Sigala I Papapetropoulos A Papiris S Light RW Roussos C Angiopoietin-2 levels are elevated in exudative pleural effusions Chest 2006 129 1259 1266 16685017 10.1378/chest.129.5.1259

28. Parikh SM Mammoto T Schultz A Yuan HT Christiani D Karumanchi SA Sukhatme VP Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans PLoS Med 2006 3 e46 16417407 10.1371/journal.pmed.0030046 PMC1334221

29. Gallagher DC Parikh SM Balonov K Miller A Gautam S Talmor D Sukhatme VP Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome Shock 2008 29 656 661 18091573 10.1097/shk.0b013e31815dd92f PMC4037741

30. Choudhury A Freestone B Patel J Lip GY Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis? Chest 2007 132 1913 1919 18079224 10.1378/chest.07-1565

31. Nadar SK Blann A Beevers DG Lip GY Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)] J Intern Med 2005 258 336 343 16164572 10.1111/j.1365-2796.2005.01550.x

32. Chong AY Caine GJ Freestone B Blann AD Lip GY Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure J Am Coll Cardiol 2004 43 423 428 15013125 10.1016/j.jacc.2003.08.042

33. Lee KW Lip GY Blann AD Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes Circulation 2004 110 2355 2360 15302795 10.1161/01.CIR.0000138112.90641.7F

34. Ganter MT Cohen MJ Brohi K Chesebro BB Staudenmayer KL Rahn P Christiaans SC Bir ND Pittet JF Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma? Ann Surg 2008 247 320 326 18216540 10.1097/SLA.0b013e318162d616

35. Giuliano JS Jr Lahni PM Harmon K Wong HR Doughty LA Carcillo JA Zingarelli B Sukhatme VP Parikh SM Wheeler DS Admission angiopoietin levels in children with septic shock Shock 2007 28 650 654 18092380 PMC2754128

36. Lukasz A Hellpap J Horn R Kielstein JT David S Haller H Kumpers P Circulating angiopoietin-1 and -2 in critically ill patients – development and clinical application of two new immunoassays Crit Care 2008 12 R94 18664247 10.1186/cc6966 PMC2575578

37. Orfanos SE Kotanidou A Glynos C Athanasiou C Tsigkos S Dimopoulou I Sotiropoulou C Zakynthinos S Armaganidis A Papapetropoulos A Roussos C Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators Crit Care Med 2007 35 199 206 17110873 10.1097/01.CCM.0000251640.77679.D7

38. Siner JM Bhandari V Engle KM Elias JA Siegel MD Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis Shock 2008 10.1097/SHK.0b013e318188bd06 18791490

39. Heijden M van der Nieuw Amerongen GP Koolwijk P van Hinsbergh VW Groeneveld AB Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients Thorax 2008 63 903 909 18559364 10.1136/thx.2007.087387

40. Shapiro NI Yano K Okada H Fischer C Howell M Spokes KC Ngo L Angus DC Aird WC A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis Shock 2008 29 452 457 18598002 10.1097/shk.0b013e31815072c1 PMC5378494

41. Flier M van der van Leeuwen HJ van Kessel KP Kimpen JL Hoepelman AI Geelen SP Plasma vascular endothelial growth factor in severe sepsis Shock 2005 23 35 38 15614129 10.1097/01.shk.0000150728.91155.41

42. Pickkers P Sprong T Eijk L Hoeven H van der Smits P Deuren M Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability Shock 2005 24 508 512 16317379 10.1097/01.shk.0000190827.36406.6e

43. Suri C Jones PF Patan S Bartunkova S Maisonpierre PC Davis S Sato TN Yancopoulos GD Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 1996 87 1171 1180 8980224 10.1016/s0092-8674(00)81813-9

44. Maisonpierre PC Suri C Jones PF Bartunkova S Wiegand SJ Radziejewski C Compton D McClain J Aldrich TH Papadopoulos N Daly TJ Davis S Sato TN Yancopoulos GD Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 1997 277 55 60 9204896 10.1126/science.277.5322.55

45. Makinde T Agrawal DK Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease J Cell Mol Med 2008 12 810 828 18266978 10.1111/j.1582-4934.2008.00254.x PMC4401129

46. Davis S Aldrich TH Jones PF Acheson A Compton DL Jain V Ryan TE Bruno J Radziejewski C Maisonpierre PC Yancopoulos GD Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning Cell 1996 87 1161 1169 8980223 10.1016/s0092-8674(00)81812-7

47. Jones N Iljin K Dumont DJ Alitalo K Tie receptors: new modulators of angiogenic and lymphangiogenic responses Nat Rev Mol Cell Biol 2001 2 257 267 11283723 10.1038/35067005

48. Kim KT Choi HH Steinmetz MO Maco B Kammerer RA Ahn SY Kim HZ Lee GM Koh GY Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2 J Biol Chem 2005 280 20126 20131 15769741 10.1074/jbc.M500292200

49. Davis S Papadopoulos N Aldrich TH Maisonpierre PC Huang T Kovac L Xu A Leidich R Radziejewska E Rafique A Goldberg J Jain V Bailey K Karow M Fandl J Samuelsson SJ Ioffe E Rudge JS Daly TJ Radziejewski C Yancopoulos GD Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering Nat Struct Biol 2003 10 38 44 12469114 10.1038/nsb880

50. Bogdanovic E Nguyen VP Dumont DJ Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization J Cell Sci 2006 119 3551 3560 16895971 10.1242/jcs.03077

51. Peters KG Kontos CD Lin PC Wong AL Rao P Huang L Dewhirst MW Sankar S Functional significance of Tie2 signaling in the adult vasculature Recent Prog Horm Res 2004 59 51 71 14749497 10.1210/rp.59.1.51

52. Macdonald PR Progias P Ciani B Patel S Mayer U Steinmetz MO Kammerer RA Structure of the extracellular domain of Tie receptor tyrosine kinases and localization of the angiopoietin-binding epitope J Biol Chem 2006 281 28408 28414 16849318 10.1074/jbc.M605219200

53. Hubbard SR Till JH Protein tyrosine kinase structure and function Annu Rev Biochem 2000 69 373 398 10966463 10.1146/annurev.biochem.69.1.373

54. Eklund L Olsen BR Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling Exp Cell Res 2006 312 630 641 16225862 10.1016/j.yexcr.2005.09.002

55. Jones N Master Z Jones J Bouchard D Gunji Y Sasaki H Daly R Alitalo K Dumont DJ Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration J Biol Chem 1999 274 30896 30905 10521483 10.1074/jbc.274.43.30896

56. Reusch P Barleon B Weindel K Martiny-Baron G Godde A Siemeister G Marme D Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood Angiogenesis 2001 4 123 131 11806244 10.1023/a:1012226627813

57. Findley CM Cudmore MJ Ahmed A Kontos CD VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling Arterioscler Thromb Vasc Biol 2007 27 2619 2626 17901375 10.1161/ATVBAHA.107.150482

58. Marron MB Singh H Tahir TA Kavumkal J Kim HZ Koh GY Brindle NP Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2 J Biol Chem 2007 282 30509 30517 17728252 10.1074/jbc.M702535200 PMC2270410

59. Yuan HT Venkatesha S Chan B Deutsch U Mammoto T Sukhatme VP Woolf AS Karumanchi SA Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival FASEB J 2007 21 3171 3183 17504972 10.1096/fj.07-8487com

60. Kim KL Shin IS Kim JM Choi JH Byun J Jeon ES Suh W Kim DK Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells Cardiovasc Res 2006 72 394 402 17054925 10.1016/j.cardiores.2006.08.002

61. Hirschberg R Wang S Mitu GM Functional symbiosis between endothelium and epithelial cells in glomeruli Cell Tissue Res 2008 331 485 493 17999087 10.1007/s00441-007-0526-z

62. Wong AL Haroon ZA Werner S Dewhirst MW Greenberg CS Peters KG Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues Circ Res 1997 81 567 574 9314838 10.1161/01.res.81.4.567

63. Armulik A Abramsson A Betsholtz C Endothelial/pericyte interactions Circ Res 2005 97 512 523 16166562 10.1161/01.RES.0000182903.16652.d7

64. Bergers G Song S The role of pericytes in blood-vessel formation and maintenance Neuro Oncol 2005 7 452 464 16212810 10.1215/S1152851705000232 PMC1871727

65. Saharinen P Eklund L Miettinen J Wirkkala R Anisimov A Winderlich M Nottebaum A Vestweber D Deutsch U Koh GY Olsen BR Alitalo K Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts Nat Cell Biol 2008 10 527 537 18425119 10.1038/ncb1715

66. Metcalf DJ Nightingale TD Zenner HL Lui-Roberts WW Cutler DF Formation and function of Weibel-Palade bodies J Cell Sci 2008 121 19 27 18096688 10.1242/jcs.03494

67. Fiedler U Scharpfenecker M Koidl S Hegen A Grunow V Schmidt JM Kriz W Thurston G Augustin HG The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies Blood 2004 103 4150 4156 14976056 10.1182/blood-2003-10-3685

68. Rondaij MG Bierings R Kragt A van Mourik JA Voorberg J Dynamics and plasticity of Weibel-Palade bodies in endothelial cells Arterioscler Thromb Vasc Biol 2006 26 1002 1007 16469951 10.1161/01.ATV.0000209501.56852.6c

69. Lewis CE De PM Naldini L Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2 Cancer Res 2007 67 8429 8432 17875679 10.1158/0008-5472.CAN-07-1684

70. De Palma M Murdoch C Venneri MA Naldini L Lewis CE Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications Trends Immunol 2007 28 519 524 17981504 10.1016/j.it.2007.09.004

71. Yoon MJ Cho CH Lee CS Jang IH Ryu SH Koh GY Localization of Tie2 and phospholipase D in endothelial caveolae is involved in angiopoietin-1-induced MEK/ERK phosphorylation and migration in endothelial cells Biochem Biophys Res Commun 2003 308 101 105 12890486 10.1016/s0006-291x(03)01341-x

72. Ward EG Grosios K Markham AF Jones PF Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2 Cytogenet Cell Genet 2001 94 147 154 11856872 10.1159/000048807

73. Oh H Takagi H Suzuma K Otani A Matsumura M Honda Y Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells J Biol Chem 1999 274 15732 15739 10336473 10.1074/jbc.274.22.15732

74. Mandriota SJ Pepper MS Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia Circ Res 1998 83 852 859 9776732 10.1161/01.res.83.8.852

75. Daly C Pasnikowski E Burova E Wong V Aldrich TH Griffiths J Ioffe E Daly TJ Fandl JP Papadopoulos N McDonald DM Thurston G Yancopoulos GD Rudge JS Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells Proc Natl Acad Sci USA 2006 103 15491 15496 17030814 10.1073/pnas.0607538103 PMC1592534

76. Hegen A Koidl S Weindel K Marme D Augustin HG Fiedler U Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements Arterioscler Thromb Vasc Biol 2004 24 1803 1809 15284088 10.1161/01.ATV.0000140819.81839.0e

77. Hasegawa Y Abe M Yamazaki T Niizeki O Shiiba K Sasaki I Sato Y Transcriptional regulation of human angiopoietin-2 by transcription factor Ets-1 Biochem Biophys Res Commun 2004 316 52 58 15003510 10.1016/j.bbrc.2004.02.019

78. Park EH Lee JM Blais JD Bell JC Pelletier J Internal translation initiation mediated by the angiogenic factor Tie2 J Biol Chem 2005 280 20945 20953 15802272 10.1074/jbc.M412744200

79. Mehta D Malik AB Signaling mechanisms regulating endothelial permeability Physiol Rev 2006 86 279 367 16371600 10.1152/physrev.00012.2005

80. Mammoto T Parikh SM Mammoto A Gallagher D Chan B Mostoslavsky G Ingber DE Sukhatme VP Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo J Biol Chem 2007 282 23910 23918 17562701 10.1074/jbc.M702169200

81. Abdel-Malak NA Harfouche R Hussain SN Transcriptome of angiopoietin 1-activated human umbilical vein endothelial cells Endothelium 2007 14 285 302 18080866 10.1080/10623320701678268

82. Chen SH Babichev Y Rodrigues N Voskas D Ling L Nguyen VP Dumont DJ Gene expression analysis of Tek/Tie2 signaling Physiol Genomics 2005 22 257 267 15899944 10.1152/physiolgenomics.00063.2005

83. Babaei S Teichert-Kuliszewska K Zhang Q Jones N Dumont DJ Stewart DJ Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide Am J Pathol 2003 162 1927 1936 12759249 10.1016/S0002-9440(10)64326-X PMC1868142

84. Harfouche R Hassessian HM Guo Y Faivre V Srikant CB Yancopoulos GD Hussain SN Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells Microvasc Res 2002 64 135 147 12074640 10.1006/mvre.2002.2421

85. Kim I Kim HG Moon SO Chae SW So JN Koh KN Ahn BC Koh GY Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion Circ Res 2000 86 952 959 10807867 10.1161/01.res.86.9.952

86. Brkovic A Pelletier M Girard D Sirois MG Angiopoietin chemotactic activities on neutrophils are regulated by PI-3K activation J Leukoc Biol 2007 81 1093 1101 17215522 10.1189/jlb.0906580

87. Harfouche R Gratton JP Yancopoulos GD Noseda M Karsan A Hussain SN Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases FASEB J 2003 17 1523 1525 12824293 10.1096/fj.02-0698fje

88. Harfouche R Hussain SN Signaling and regulation of endothelial cell survival by angiopoietin-2 Am J Physiol Heart Circ Physiol 2006 291 H1635 H1645 16714355 10.1152/ajpheart.01318.2005

89. Kim I Kim JH Moon SO Kwak HJ Kim NG Koh GY Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway Oncogene 2000 19 4549 4552 11002428 10.1038/sj.onc.1203800

90. Maliba R Lapointe S Neagoe PE Brkovic A Sirois MG Angiopoietins-1 and -2 are both capable of mediating endothelial PAF synthesis: intracellular signalling pathways Cell Signal 2006 18 1947 1957 16617006 10.1016/j.cellsig.2006.02.015

91. Abdel-Malak NA Srikant CB Kristof AS Magder SA Di Battista JA Hussain SN Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8 Blood 2008 111 4145 4154 18252863 10.1182/blood-2007-08-110338

92. Daly C Wong V Burova E Wei Y Zabski S Griffiths J Lai KM Lin HC Ioffe E Yancopoulos GD Rudge JS Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) Genes Dev 2004 18 1060 1071 15132996 10.1101/gad.1189704 PMC406295

93. Tadros A Hughes DP Dunmore BJ Brindle NP ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1 Blood 2003 102 4407 4409 12933576 10.1182/blood-2003-05-1602

94. Harfouche R Malak NA Brandes RP Karsan A Irani K Hussain SN Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling FASEB J 2005 19 1728 1730 16049136 10.1096/fj.04-3621fje

95. Fukuhara S Sako K Minami T Noda K Kim HZ Kodama T Shibuya M Takakura N Koh GY Mochizuki N Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1 Nat Cell Biol 2008 10 513 526 18425120 10.1038/ncb1714

96. Lobov IB Brooks PC Lang RA Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo Proc Natl Acad Sci USA 2002 99 11205 11210 12163646 10.1073/pnas.172161899 PMC123234

97. Nguyen VP Chen SH Trinh J Kim H Coomber BL Dumont DJ Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2 BMC Cell Biol 2007 8 10 17341311 10.1186/1471-2121-8-10 PMC1828055

98. Teichert-Kuliszewska K Maisonpierre PC Jones N Campbell AI Master Z Bendeck MP Alitalo K Dumont DJ Yancopoulos GD Stewart DJ Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2 Cardiovasc Res 2001 49 659 670 11166279 10.1016/s0008-6363(00)00231-5

99. Imhof BA urrand-Lions M Angiogenesis and inflammation face off Nat Med 2006 12 171 172 16462798 10.1038/nm0206-171

100. Frantz S Vincent KA Feron O Kelly RA Innate immunity and angiogenesis Circ Res 2005 96 15 26 15637304 10.1161/01.RES.0000153188.68898.ac

101. Hamik A Wang B Jain MK Transcriptional regulators of angiogenesis Arterioscler Thromb Vasc Biol 2006 26 1936 1947 16778118 10.1161/01.ATV.0000232542.42968.e3

102. Davis GE Senger DR Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression Curr Opin Hematol 2008 15 197 203 18391785 10.1097/MOH.0b013e3282fcc321

103. Scharpfenecker M Fiedler U Reiss Y Augustin HG The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism J Cell Sci 2005 118 771 780 15687104 10.1242/jcs.01653

104. Aplin AC Gelati M Fogel E Carnevale E Nicosia RF Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis Physiol Genomics 2006 27 20 28 17018690 10.1152/physiolgenomics.00048.2006

105. Uemura A Ogawa M Hirashima M Fujiwara T Koyama S Takagi H Honda Y Wiegand SJ Yancopoulos GD Nishikawa S Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells J Clin Invest 2002 110 1619 1628 12464667 10.1172/JCI15621 PMC151628

106. Ramsauer M D'Amore PA Contextual role for angiopoietins and TGFbeta1 in blood vessel stabilization J Cell Sci 2007 120 1810 1817 17502485 10.1242/jcs.003533

107. Kwak HJ So JN Lee SJ Kim I Koh GY Angiopoietin-1 is an apoptosis survival factor for endothelial cells FEBS Lett 1999 448 249 253 10218485 10.1016/s0014-5793(99)00378-6

108. Papapetropoulos A Garcia-Cardena G Dengler TJ Maisonpierre PC Yancopoulos GD Sessa WC Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors Lab Invest 1999 79 213 223 10068209

109. Papapetropoulos A Fulton D Mahboubi K Kalb RG O'Connor DS Li F Altieri DC Sessa WC Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway J Biol Chem 2000 275 9102 9105 10734041 10.1074/jbc.275.13.9102

110. Morrow D Cullen JP Cahill PA Redmond EM Cyclic strain regulates the Notch/CBF-1 signaling pathway in endothelial cells: role in angiogenic activity Arterioscler Thromb Vasc Biol 2007 27 1289 1296 17395855 10.1161/ATVBAHA.107.142778

111. Murdoch C Tazzyman S Webster S Lewis CE Expression of Tie-2 by human monocytes and their responses to angiopoietin-2 J Immunol 2007 178 7405 7411 17513791 10.4049/jimmunol.178.11.7405

112. Chen-Konak L Guetta-Shubin Y Yahav H Shay-Salit A Zilberman M Binah O Resnick N Transcriptional and post-translation regulation of the Tie1 receptor by fluid shear stress changes in vascular endothelial cells FASEB J 2003 17 2121 2123 14500555 10.1096/fj.02-1151fje

113. Witzenbichler B Maisonpierre PC Jones P Yancopoulos GD Isner JM Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2 J Biol Chem 1998 273 18514 18521 9660821 10.1074/jbc.273.29.18514

114. Rao S Lobov IB Vallance JE Tsujikawa K Shiojima I Akunuru S Walsh K Benjamin LE Lang RA Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch Development 2007 134 4449 4458 18039971 10.1242/dev.012187 PMC3675770

115. Roviezzo F Tsigkos S Kotanidou A Bucci M Brancaleone V Cirino G Papapetropoulos A Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage J Pharmacol Exp Ther 2005 314 738 744 15870388 10.1124/jpet.105.086553

116. Feraud O Mallet C Vilgrain I Expressional regulation of the angiopoietin-1 and -2 and the endothelial-specific receptor tyrosine kinase Tie2 in adrenal atrophy: a study of adrenocorticotropin-induced repair Endocrinology 2003 144 4607 4615 12960064 10.1210/en.2003-0099

117. Fiedler U Augustin HG Angiopoietins: a link between angiogenesis and inflammation Trends Immunol 2006 27 552 558 17045842 10.1016/j.it.2006.10.004

118. Baffert F Le T Thurston G McDonald DM Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules Am J Physiol Heart Circ Physiol 2006 290 H107 H118 16126815 10.1152/ajpheart.00542.2005

119. Thurston G Rudge JS Ioffe E Zhou H Ross L Croll SD Glazer N Holash J McDonald DM Yancopoulos GD Angiopoietin-1 protects the adult vasculature against plasma leakage Nat Med 2000 6 460 463 10742156 10.1038/74725

120. Kim I Oh JL Ryu YS So JN Sessa WC Walsh K Koh GY Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells FASEB J 2002 16 126 128 11729102 10.1096/fj.01-0556fje

121. Gamble JR Drew J Trezise L Underwood A Parsons M Kasminkas L Rudge J Yancopoulos G Vadas MA Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions Circ Res 2000 87 603 607 11009566 10.1161/01.res.87.7.603

122. Kim I Moon SO Park SK Chae SW Koh GY Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression Circ Res 2001 89 477 479 11557733 10.1161/hh1801.097034

123. Pizurki L Zhou Z Glynos K Roussos C Papapetropoulos A Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production Br J Pharmacol 2003 139 329 336 12770938 10.1038/sj.bjp.0705259 PMC1573855

124. Satchell SC Anderson KL Mathieson PW Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties J Am Soc Nephrol 2004 15 566 574 14978158 10.1097/01.asn.0000115397.22519.03

125. Fiedler U Reiss Y Scharpfenecker M Grunow V Koidl S Thurston G Gale NW Witzenrath M Rosseau S Suttorp N Sobke A Herrmann M Preissner KT Vajkoczy P Augustin HG Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation Nat Med 2006 12 235 239 16462802 10.1038/nm1351

126. Park YS Kim NH Jo I Hypoxia and vascular endothelial growth factor acutely up-regulate angiopoietin-1 and Tie2 mRNA in bovine retinal pericytes Microvasc Res 2003 65 125 131 12686170 10.1016/s0026-2862(02)00035-3

127. Pichiule P Chavez JC LaManna JC Hypoxic regulation of angiopoietin-2 expression in endothelial cells J Biol Chem 2004 279 12171 12180 14702352 10.1074/jbc.M305146200

128. Mofarrahi M Nouh T Qureshi S Guillot L Mayaki D Hussain SN Regulation of angiopoietin expression by bacterial lipopolysaccharide Am J Physiol Lung Cell Mol Physiol 2008 294 L955 L963 18310225 10.1152/ajplung.00449.2007

129. Karmpaliotis D Kosmidou I Ingenito EP Hong K Malhotra A Sunday ME Haley KJ Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury Am J Physiol Lung Cell Mol Physiol 2002 283 L585 L595 12169578 10.1152/ajplung.00048.2002

130. Mei SH McCarter SD Deng Y Parker CH Liles WC Stewart DJ Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1 PLoS Med 2007 4 e269 17803352 10.1371/journal.pmed.0040269 PMC1961632

131. Hangai M He S Hoffmann S Lim JI Ryan SJ Hinton DR Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells J Neuroimmunol 2006 171 45 56 16288810 10.1016/j.jneuroim.2005.09.018

132. Kim I Kim JH Ryu YS Liu M Koh GY Tumor necrosis factor-alpha upregulates angiopoietin-2 in human umbilical vein endothelial cells Biochem Biophys Res Commun 2000 269 361 365 10708557 10.1006/bbrc.2000.2296

133. Hashimoto T Wu Y Boudreau N Li J Matsumoto M Young W Regulation of tie2 expression by angiopoietin – potential feedback system Endothelium 2004 11 207 210 15370298 10.1080/10623320490512417

134. Mangan SH Campenhout AV Rush C Golledge J Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2 Cardiovasc Res 2007 76 494 505 17706953 10.1016/j.cardiores.2007.07.017 PMC2128766

135. Maliba R Brkovic A Neagoe PE Villeneuve LR Sirois MG Angiopoietin-mediated endothelial P-selectin translocation: cell signaling mechanisms J Leukoc Biol 2008 83 352 360 17984290 10.1189/jlb.0107056

136. Bezuidenhout L Bracher M Davison G Zilla P Davies N Ang-2 and PDGF-BB cooperatively stimulate human peripheral blood monocyte fibrinolysis J Leukoc Biol 2007 81 1496 1503 17395886 10.1189/jlb.1106687

137. Lemieux C Maliba R Favier J Theoret JF Merhi Y Sirois MG Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses Blood 2005 105 1523 1530 15498854 10.1182/blood-2004-09-3531

138. Childs EW Tharakan B Byrge N Tinsley JH Hunter FA Smythe WR Angiopoietin-1 inhibits intrinsic apoptotic signaling and vascular hyperpermeability following hemorrhagic shock Am J Physiol Heart Circ Physiol 2008 294 H2285 H2295 18344375 10.1152/ajpheart.01361.2007

139. Dallabrida SM Ismail N Oberle JR Himes BE Rupnick MA Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins Circ Res 2005 96 e8 24 15692086 10.1161/01.RES.0000158285.57191.60

140. Childs EW Tharakan B Hunter FA Tinsley JH Cao X Apoptotic signaling induces hyperpermeability following hemorrhagic shock Am J Physiol Heart Circ Physiol 2007 292 H3179 H3189 17307990 10.1152/ajpheart.01337.2006

141. Tharakan B Holder-Haynes JG Hunter FA Childs EW Alpha lipoic acid attenuates microvascular endothelial cell hyperpermeability by inhibiting the intrinsic apoptotic signaling Am J Surg 2008 195 174 178 18096126 10.1016/j.amjsurg.2007.09.028

142. Davidson MT Deitch EA Lu Q Hasko G Abungu B Nemeth ZH Zaets SB Gaspers LD Thomas AP Xu DZ Traumahemorrhagic shock mesenteric lymph induces endothelial apoptosis that involves both caspase-dependent and caspase-independent mechanisms Ann Surg 2004 240 123 131 15213628 10.1097/01.sla.0000129341.94219.cf PMC1356384

143. Heijden M van der Versteilen AM Sipkema P van Nieuw Amerongen GP Musters RJ Groeneveld AB Rhokinase-dependent F-actin rearrangement is involved in the inhibition of PI3-kinase/Akt during ischemia-reperfusion-induced endothelial cell apoptosis Apoptosis 2008 13 404 412 18165899 10.1007/s10495-007-0173-6 PMC2257993

144. Serini G Napione L Arese M Bussolino F Besides adhesion: new perspectives of integrin functions in angiogenesis Cardiovasc Res 2008 78 213 222 18285512 10.1093/cvr/cvn045

145. Carlson TR Feng Y Maisonpierre PC Mrksich M Morla AO Direct cell adhesion to the angiopoietins mediated by integrins J Biol Chem 2001 276 26516 26525 11346644 10.1074/jbc.M100282200

146. Weber CC Cai H Ehrbar M Kubota H Martiny-Baron G Weber W Djonov V Weber E Mallik AS Fussenegger M Frei K Hubbell JA Zisch AH Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization J Biol Chem 2005 280 22445 22453 15781448 10.1074/jbc.M410367200

147. Dejana E Orsenigo F Lampugnani MG The role of adherens junctions and VE-cadherin in the control of vascular permeability J Cell Sci 2008 121 2115 2122 18565824 10.1242/jcs.017897

148. Shay-Salit A Shushy M Wolfovitz E Yahav H Breviario F Dejana E Resnick N VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells Proc Natl Acad Sci USA 2002 99 9462 9467 12080144 10.1073/pnas.142224299 PMC123163

149. Wang Y Pampou S Fujikawa K Varticovski L Opposing effect of angiopoietin-1 on VEGF-mediated disruption of endothelial cell-cell interactions requires activation of PKC beta J Cell Physiol 2004 198 53 61 14584044 10.1002/jcp.10386

150. Gavard J Patel V Gutkind JS Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia Dev Cell 2008 14 25 36 18194650 10.1016/j.devcel.2007.10.019

151. Cascone I Napione L Maniero F Serini G Bussolino F Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1 J Cell Biol 2005 170 993 1004 16157706 10.1083/jcb.200507082 PMC2171441

152. David S Kumpers P Hellpap J Horn R Holger L Kielstein JT Haller H Elevated serum angiopoietin-2 correlates with degree of arteriosclerosis in CKD V patients J Am Soc Nephrol 2007

153. Pfaff D Fiedler U Augustin HG Emerging roles of the angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking J Leukoc Biol 2006 80 719 726 16864601 10.1189/jlb.1105652

154. Methe H Hess S Edelman ER Endothelial immunogenicity: a matter of matrix microarchitecture Thromb Haemost 2007 98 278 282 17721607

155. Methe H Balcells M Alegret MC Santacana M Molins B Hamik A Jain MK Edelman ER Vascular bed origin dictates flow pattern regulation of endothelial adhesion molecule expression Am J Physiol Heart Circ Physiol 2007 292 H2167 H2175 17209004 10.1152/ajpheart.00403.2006

156. Griffioen AW Molema G Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacol Rev 2000 52 237 268 10835101

157. Griffin RJ Molema G Dings RP Angiogenesis treatment, new concepts on the horizon Angiogenesis 2006 9 67 72 16964528 10.1007/s10456-006-9031-3

158. Niu Q Perruzzi C Voskas D Lawler J Dumont DJ Benjamin LE Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1 Cancer Biol Ther 2004 3 402 405 14739779 10.4161/cbt.3.4.735

159. Kerbel RS Tumor angiogenesis N Engl J Med 2008 358 2039 2049 18463380 10.1056/NEJMra0706596 PMC4542009

160. Chae JK Kim I Lim ST Chung MJ Kim WH Kim HG Ko JK Koh GY Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization Arterioscler Thromb Vasc Biol 2000 20 2573 2578 11116055 10.1161/01.atv.20.12.2573

161. Ryu JK Cho CH Shin HY Song SU Oh SM Lee M Piao S Han JY Kim IH Koh GY Suh JK Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia Mol Ther 2006 13 705 715 16380295 10.1016/j.ymthe.2005.10.016

162. Holash J Thurston G Rudge JS Yancopoulos GD Adjei AA Bergers G Pytowski B Pegram M Gordon MS Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents Cancer Metastasis Rev 2006 25 243 252 16770536 10.1007/s10555-006-8504-6

163. Koh GY Kim I Kwak HJ Yun MJ Leem JC Biomedical significance of endothelial cell specific growth factor, angiopoietin Exp Mol Med 2002 34 1 11 11989972 10.1038/emm.2002.1

164. Hashimoto T Pittet JF Angiopoietin-2: modulator of vascular permeability in acute lung injury? PLoS Med 2006 3 e113 16441182 10.1371/journal.pmed.0030113 PMC1360081

165. Cho CH Kammerer RA Lee HJ Steinmetz MO Ryu YS Lee SH Yasunaga K Kim KT Kim I Choi HH Kim W Kim SH Park SK Lee GM Koh GY COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity Proc Natl Acad Sci USA 2004 101 5547 5552 15060279 10.1073/pnas.0307574101 PMC397420

166. Lee S Kim W Moon SO Sung MJ Kim DH Kang KP Jang KY Lee SY Park BH Koh GY Park SK Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes Nephrol Dial Transplant 2007 22 396 408 17085463 10.1093/ndt/gfl598

167. Tuo QH Zeng H Stinnett A Yu H Aschner JL Liao DF Chen JX Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis Am J Physiol Heart Circ Physiol 2008 294 H2547 H2557 18408125 10.1152/ajpheart.01250.2007

168. Thebaud B Ladha F Michelakis ED Sawicka M Thurston G Eaton F Hashimoto K Harry G Haromy A Korbutt G Archer SL Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization Circulation 2005 112 2477 2486 16230500 10.1161/CIRCULATIONAHA.105.541524

169. Witzenbichler B Westermann D Knueppel S Schultheiss HP Tschope C Protective role of angiopoietin-1 in endotoxic shock Circulation 2005 111 97 105 15611372 10.1161/01.CIR.0000151287.08202.8E

170. Lee JS Song SH Kim JM Shin IS Kim KL Suh YL Kim HZ Koh GY Byun J Jeon ES Suh W Kim DK Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor Cardiovasc Res 2008 78 572 580 18285514 10.1093/cvr/cvn048 PMC5436684

171. Aghai ZH Faqiri S Saslow JG Nakhla T Farhath S Kumar A Eydelman R Strande L Stahl G Leone P Bhandari V Angiopoietin 2 concentrations in infants developing bronchopulmonary dysplasia: attenuation by dexamethasone J Perinatol 2008 28 149 155 18033304 10.1038/sj.jp.7211886

172. Sarraf-Yazdi S Mi J Moeller BJ Niu X White RR Kontos CD Sullenger BA Dewhirst MW Clary BM Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer J Surg Res 2008 146 16 23 17950331 10.1016/j.jss.2007.04.028

173. Grimm D Kay MA Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007 117 3633 3641 18060021 10.1172/JCI34129 PMC2096424

174. Dewachter L Adnot S Fadel E Humbert M Maitre B Barlier-Mur AM Simonneau G Hamon M Naeije R Eddahibi S Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension Am J Respir Crit Care Med 2006 174 1025 1033 16917117 10.1164/rccm.200602-304OC

175. Nomura S Kanazawa H Hirata K Iwao H Yoshikawa J Relationship between vascular endothelial growth factor and angio-poietin-2 in asthmatics before and after inhaled beclomethasone therapy J Asthma 2005 42 141 146 15871447

176. Anargyrou K Terpos E Vassilakopoulos TP Pouli A Sachanas S Tzenou T Masouridis S Christoulas D Angelopoulou MK Dimitriadou EM Kalpadakis C Tsionos K Panayiotidis P Dimopoulos MA Pangalis GA Kyrtsonis MC Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib Haematologica 2008 93 451 454 18287135 10.3324/haematol.11852

177. Park JH Park KJ Kim YS Sheen SS Lee KS Lee HN Oh YJ Hwang SC Serum angiopoietin-2 as a clinical marker for lung cancer Chest 2007 132 200 206 17505039 10.1378/chest.06-2915

178. Kumpers P Koenecke C Hecker H Hellpap J Horn R Verhagen W Buchholz S Hertenstein B Krauter J Eder M David S Gohring G Haller H Ganser A Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies Blood 2008 112 2139 2148 18483397 10.1182/blood-2007-12-130021

179. Ledford H The full cycle Nature 2008 453 843 845 18548044 10.1038/453843a

180. Gallagher DC Bhatt RS Parikh SM Patel P Seery V McDermott DF Atkins MB Sukhatme VP Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak Clin Cancer Res 2007 13 2115 2120 17404094 10.1158/1078-0432.CCR-06-2509

181. Scholz A Rehm VA Rieke S Derkow K Schulz P Neumann K Koch I Pascu M Wiedenmann B Berg T Schott E Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma Am J Gastroenterol 2007 102 2471 2481 17581268 10.1111/j.1572-0241.2007.01377.x